三氧化二砷对人雌激素受体阴性乳腺癌细胞株作用的研究
摘要
乳腺癌是全世界妇女中发病率最高的恶性肿瘤,也是临床上最常见的激素依赖性肿瘤。根据ER表型差异,乳腺癌被分为两种:ER阳性乳腺癌和ER阴性乳腺癌。大约2/3乳腺癌患者呈ER阳性,肿瘤细胞生长具有雌激素依赖性,对于这类患者,临床上常采取撤除雌激素的内分泌治疗方法。大约1/3乳腺癌患者为ER阴性,与ER阳性乳腺癌相比,其恶性度较高,对内分泌治疗不敏感,目前尚无理想的治疗方法,预后较差。若能诱导ER阴性乳腺癌细胞凋亡,将为ER阴性乳腺癌患者的治疗开辟新的治疗途径,为这些患者带来希望。
三氧化二砷(分子式As_2O_3)为无机化合物,是中药砒霜的提取物,有剧毒。长期以来As_2O_3的药用价值被其剧毒性所掩盖。现在随着质控技术的发达和对As_2O_3实验及临床研究的深入,As_2O_3在肿瘤治疗方面的临床应用范围越来越广泛。现代药理研究说明,三氧化二砷对白血病和许多实体瘤有不同程度的抑制作用,中医文献也有不少有关砒霜治疗肿瘤的记载。以此为依据,本实验以MDA-MB-435S细胞为研究对象,研究三氧化二砷对雌激素受体阴性乳腺癌细胞株的细胞生长、细胞形态、细胞周期、细胞凋亡及凋亡相关基因的影响情况,探讨三氧化二砷对ER阴性乳腺癌细胞株的作用机制,在中医治疗ER阴性乳腺癌方面开辟了新思路。
【目的】
以雌激素受体阴性乳腺癌细胞株MDA-MB-435S为研究对象,研究三氧化二砷对MDA-MB-435S细胞增殖、细胞周期、凋亡的影响,并研究其可能的作用机制。
【方法】
实验分六部分:MTT实验、光镜观察细胞形态、流式PI单染检测细胞周期和凋亡、流式Annexin V/PI双染检测细胞凋亡、免疫组化检测细胞内Bcl-2和Bax表达情况、PI 33342荧光染色观察细胞凋亡。在体外培养雌激素受体阴性乳腺癌细胞株MDA-MB-435S,采用不同浓度连续作用于细胞。通过MTT比色实验,观察不同施加因素对细胞生长的影响,并根据MTT实验结果初步筛选三氧化二砷的作用浓度,在量效曲线1.75-28μg/ml的线性关系范围内,在IC_(50)值为10.47μg/mL上下选取三氧化二砷的加药浓度,设对照组和加药组(1、5、10、15、20μg/ml)进行流式细胞仪技术检测细胞周期及凋亡的变化,根据流式检测结果选取对照组和加药组(0.25、0.5、1、5、10μg/ml)进行免疫组化检测Bcl-2和Bax的变化,并通过PI 33342荧光染色实验观察细胞凋亡情况。
【结果】
1.大于1.75μg/ml的三氧化二砷能明显抑制MDA-MB-435S细胞生长,在1.75～28μg/ml浓度范围内抑制作用明显(P＜0.001),且有剂量依赖效应。
2.三氧化二砷可以使MDA-MB-435S细胞周期中的G0-G1期细胞比率增高,G2/M期细胞比率增高,S期细胞比率下降,与对照组比,结果均有显著性差异(p＜0.05)。
3.流式PI单染结果显示:1、5、10、15、20μg/ml浓度范围内,MDA-MB-435S细胞未见明显凋亡,而MCF-7细胞可见明显凋亡(p＜0.05)。
4.Annexin V/PI双染结果显示:1、5、10、15、20μg/ml浓度与对照组相比,MDA-MB-435S细胞的早期凋亡率未见显著性差异;0.25、0.5、1、1.5、2μg/ml浓度与对照组相比,MDA-MB-435S细胞的早期凋亡率均有显著性差异(p＜0.05),且随加药浓度的增加凋亡率明显增高。说明低浓度三氧化二砷可能诱导MDA-MB-435S细胞凋亡。
5.免疫组化结果显示:三氧化二砷组(0.25、0.5、1、5、10μg/ml)与对照组相比,可以下调BCL-2表达和BAX表达。
6.PI 33342荧光染色结果显示:相同条件下,三氧化二砷组(0.25、0.5、1、5、10μg/ml)与空白对照组相比,MDA-MB-435S细胞未见明显凋亡细胞形态,MCF-7细胞可见凋亡细胞形态。
【结论】
1.三氧化二砷作用于MDA-MB-435S细胞可抑制细胞增殖。
2.三氧化二砷可阻滞MDA-MB-435S细胞周期在G0-G1和G2-M期,使进入S期细胞减少,可能诱导MDA-MB-435S细胞凋亡。
3.三氧化二砷可以下调BCL-2表达和BAX表达,三氧化二砷可能是通过下调BCL-2表达的方式来达到抑制MDA-MB-435S细胞生长的作用,但三氧化二砷对MDA-MB-435S细胞抑制作用的方式有待进一步研究。
Women breast cancer is the world's highest incidence of malignant tumor,and is clinically the most common hormone-dependent tumor. According to phenotypic differences in ER breast cancer were divided into two types:ER-positive breast cancer and ER-negative breast cancer.About 2 / 3 were ER-positive breast cancer patients,tumor cell growth with estrogen-dependent.For such patients,clinicians often take estrogen removal of endocrine treatment.Approximately 1 / 3 for ER-negative breast cancer patients with ER-positive breast cancer compared to a higher grade, is not sensitive to endocrine therapy,there is no ideal method of treatment, poor prognosis.If the induction of apoptosis in ER-negative breast cancer will be ER-negative breast cancer patients to open up new therapeutic approaches,in order to bring hope to these patients.
As_2O_3 which is inorganic compounds,is Chinese medicine extract arsenic, having Highly toxic.A long period of time,the medicinal value of As_2O_3 has been overshadowed by its highly toxic.Now,with advanced quality control technology and deep studies on experimental and clinical of As_2O_3,its treatment of Cancer Clinical application is more and more wide. Modern pharmacological studies indicated that,As_2O_3 has varying degrees of inhibition for leukemia and many solid tumors.Chinese medicine also has a lot of literature on the arsenic treatment of documented tumor. In the experiment,we study that arsenic trioxide roles in estrogen receptor-negative breast cancer cell lines MDA-MB-435S of cell growth, cell morphology,cell cycle,apoptosis and apoptosis-related gene effect.We investigate the effect of arsenic trioxide on the ER-negative breast cancer cell lines the role of mechanisms of Chinese medicine treatment in ER-negative breast cancer has opened up new ideas.
Objective
To investigate the influence of arsenic on the cell proliferation, mitotic cycle and apoptosis of MDA-MB-435S and discuss the mechanism.
Method
The experiment was divided into six parts:MTT experiment,Light microscope to observe cell morphology,PI-flow single-dye experiments to measure the changes of cell cycle and apoptosis,Streaming AnnexinⅤ/ PI double staining to measure cell apoptosis,Immunohistochemical detection of intracellular Bcl-2 and Bax expression,PI 33342 fluorescent staining of apoptosis.We adopt the role of different concentrations in vitro MDA-MB-435S.The influence of different factors on growth of the cells were observed by MTT colorimetry assay and corresponding densities of As_2O_3 were screened preliminary by the results.At 1.75-28μg/ml range of linear relationship by dose-response curves,we select corresponding densities of As_2O_3 at upper and lower of IC50 value.Located the control group and the As_2O_3 group(1、5、10、15、20μg/ml),we measure the changes of cell cycle and apoptosis by flow cytometry,according to flow test results,we selecte the control group and the As_2O_3 group(1、5、10、15、20μg/ml) for being detected BCL-2 and BAX changes by immunohistochemical method.Cell apoptosis were observed by PI 33342 fluorescence staining experiments.
results
1.Greater than 1.75μg/ml arsenic trioxide could significantly inhibit the growth of MDA-MB-435S cells,and arsenic trioxide have a dose effect in 1.75～28μg/ml concentration range(P<0.001).
2.Arsenic Trioxide can make the percentage of G0-G1 stage cells and G2/M stage cells increase in the MDA-MB-435S cell cycle,and make S stage cell decrease.To contrast with control group,all of the results have significant differences(p<0.05).
3.PI-flow single-dye experiments show that MDA-MB-435S cells do not have obvious apoptosis and MCF-7 cells have obvious apoptosis in 1、5、10、15、20μg/ml(p<0.05).
4.Streaming AnnexinⅤ/ PI double staining experiments show that the early apoptosis rate of MDA-MB-435S cells have no significant difference by As_2O_3 group(1、5、10、15、20μg/ml)compared with control group,and the early apoptosis rate of MDA-MB-435S cells have significant difference by As_2O_3 group(0.25、0.5、1、1.5、2μg/ml) compared with control group.With the action dose heightening,the rate of Apoptosis will be induced to increase obviously.MDA-MB-435S cells apoptosis probably induced by low concentrations of arsenic trioxide.
5.Immunohistochemical detection experiments show that the group of Arsenic Trioxide(0.25、0.5、1、5、10μg/ml) compared with control group can down-regulate the express of BCL-2 and BAX.
6.PI 33342 fluorescent staining experiments show that,under the same conditions,the group of Arsenic Trioxide(0.25、0.5、1、5、10μg/ml )compared with control group,apoptotic cells morphology can not be seen obviously in MDA-MB-435S cells and can be seen in MCF-7 cells.
conclusion
1.arsenic trioxide can inhibit MDA-MB-435S cell proliferation.
2.Arsenic trioxide can block MDA-MB-435S cell cycle at G0-G1 and G2-M phase,so that reduction into the S phase cells,probably induced by MDA-MB-435S cell apoptosis.
3.Arsenic Trioxide can down-regulate the express of BCL-2 and BAX. Arsenic trioxide are possible through reduced expression of BCL-2 to attain the inhibition MDA-MB-435S cells.Inhibition of the way should be studied further.
三氧化二砷(分子式As_2O_3)为无机化合物,是中药砒霜的提取物,有剧毒。长期以来As_2O_3的药用价值被其剧毒性所掩盖。现在随着质控技术的发达和对As_2O_3实验及临床研究的深入,As_2O_3在肿瘤治疗方面的临床应用范围越来越广泛。现代药理研究说明,三氧化二砷对白血病和许多实体瘤有不同程度的抑制作用,中医文献也有不少有关砒霜治疗肿瘤的记载。以此为依据,本实验以MDA-MB-435S细胞为研究对象,研究三氧化二砷对雌激素受体阴性乳腺癌细胞株的细胞生长、细胞形态、细胞周期、细胞凋亡及凋亡相关基因的影响情况,探讨三氧化二砷对ER阴性乳腺癌细胞株的作用机制,在中医治疗ER阴性乳腺癌方面开辟了新思路。
【目的】
以雌激素受体阴性乳腺癌细胞株MDA-MB-435S为研究对象,研究三氧化二砷对MDA-MB-435S细胞增殖、细胞周期、凋亡的影响,并研究其可能的作用机制。
【方法】
实验分六部分:MTT实验、光镜观察细胞形态、流式PI单染检测细胞周期和凋亡、流式Annexin V/PI双染检测细胞凋亡、免疫组化检测细胞内Bcl-2和Bax表达情况、PI 33342荧光染色观察细胞凋亡。在体外培养雌激素受体阴性乳腺癌细胞株MDA-MB-435S,采用不同浓度连续作用于细胞。通过MTT比色实验,观察不同施加因素对细胞生长的影响,并根据MTT实验结果初步筛选三氧化二砷的作用浓度,在量效曲线1.75-28μg/ml的线性关系范围内,在IC_(50)值为10.47μg/mL上下选取三氧化二砷的加药浓度,设对照组和加药组(1、5、10、15、20μg/ml)进行流式细胞仪技术检测细胞周期及凋亡的变化,根据流式检测结果选取对照组和加药组(0.25、0.5、1、5、10μg/ml)进行免疫组化检测Bcl-2和Bax的变化,并通过PI 33342荧光染色实验观察细胞凋亡情况。
【结果】
1.大于1.75μg/ml的三氧化二砷能明显抑制MDA-MB-435S细胞生长,在1.75～28μg/ml浓度范围内抑制作用明显(P＜0.001),且有剂量依赖效应。
2.三氧化二砷可以使MDA-MB-435S细胞周期中的G0-G1期细胞比率增高,G2/M期细胞比率增高,S期细胞比率下降,与对照组比,结果均有显著性差异(p＜0.05)。
3.流式PI单染结果显示:1、5、10、15、20μg/ml浓度范围内,MDA-MB-435S细胞未见明显凋亡,而MCF-7细胞可见明显凋亡(p＜0.05)。
4.Annexin V/PI双染结果显示:1、5、10、15、20μg/ml浓度与对照组相比,MDA-MB-435S细胞的早期凋亡率未见显著性差异;0.25、0.5、1、1.5、2μg/ml浓度与对照组相比,MDA-MB-435S细胞的早期凋亡率均有显著性差异(p＜0.05),且随加药浓度的增加凋亡率明显增高。说明低浓度三氧化二砷可能诱导MDA-MB-435S细胞凋亡。
5.免疫组化结果显示:三氧化二砷组(0.25、0.5、1、5、10μg/ml)与对照组相比,可以下调BCL-2表达和BAX表达。
6.PI 33342荧光染色结果显示:相同条件下,三氧化二砷组(0.25、0.5、1、5、10μg/ml)与空白对照组相比,MDA-MB-435S细胞未见明显凋亡细胞形态,MCF-7细胞可见凋亡细胞形态。
【结论】
1.三氧化二砷作用于MDA-MB-435S细胞可抑制细胞增殖。
2.三氧化二砷可阻滞MDA-MB-435S细胞周期在G0-G1和G2-M期,使进入S期细胞减少,可能诱导MDA-MB-435S细胞凋亡。
3.三氧化二砷可以下调BCL-2表达和BAX表达,三氧化二砷可能是通过下调BCL-2表达的方式来达到抑制MDA-MB-435S细胞生长的作用,但三氧化二砷对MDA-MB-435S细胞抑制作用的方式有待进一步研究。
Women breast cancer is the world's highest incidence of malignant tumor,and is clinically the most common hormone-dependent tumor. According to phenotypic differences in ER breast cancer were divided into two types:ER-positive breast cancer and ER-negative breast cancer.About 2 / 3 were ER-positive breast cancer patients,tumor cell growth with estrogen-dependent.For such patients,clinicians often take estrogen removal of endocrine treatment.Approximately 1 / 3 for ER-negative breast cancer patients with ER-positive breast cancer compared to a higher grade, is not sensitive to endocrine therapy,there is no ideal method of treatment, poor prognosis.If the induction of apoptosis in ER-negative breast cancer will be ER-negative breast cancer patients to open up new therapeutic approaches,in order to bring hope to these patients.
As_2O_3 which is inorganic compounds,is Chinese medicine extract arsenic, having Highly toxic.A long period of time,the medicinal value of As_2O_3 has been overshadowed by its highly toxic.Now,with advanced quality control technology and deep studies on experimental and clinical of As_2O_3,its treatment of Cancer Clinical application is more and more wide. Modern pharmacological studies indicated that,As_2O_3 has varying degrees of inhibition for leukemia and many solid tumors.Chinese medicine also has a lot of literature on the arsenic treatment of documented tumor. In the experiment,we study that arsenic trioxide roles in estrogen receptor-negative breast cancer cell lines MDA-MB-435S of cell growth, cell morphology,cell cycle,apoptosis and apoptosis-related gene effect.We investigate the effect of arsenic trioxide on the ER-negative breast cancer cell lines the role of mechanisms of Chinese medicine treatment in ER-negative breast cancer has opened up new ideas.
Objective
To investigate the influence of arsenic on the cell proliferation, mitotic cycle and apoptosis of MDA-MB-435S and discuss the mechanism.
Method
The experiment was divided into six parts:MTT experiment,Light microscope to observe cell morphology,PI-flow single-dye experiments to measure the changes of cell cycle and apoptosis,Streaming AnnexinⅤ/ PI double staining to measure cell apoptosis,Immunohistochemical detection of intracellular Bcl-2 and Bax expression,PI 33342 fluorescent staining of apoptosis.We adopt the role of different concentrations in vitro MDA-MB-435S.The influence of different factors on growth of the cells were observed by MTT colorimetry assay and corresponding densities of As_2O_3 were screened preliminary by the results.At 1.75-28μg/ml range of linear relationship by dose-response curves,we select corresponding densities of As_2O_3 at upper and lower of IC50 value.Located the control group and the As_2O_3 group(1、5、10、15、20μg/ml),we measure the changes of cell cycle and apoptosis by flow cytometry,according to flow test results,we selecte the control group and the As_2O_3 group(1、5、10、15、20μg/ml) for being detected BCL-2 and BAX changes by immunohistochemical method.Cell apoptosis were observed by PI 33342 fluorescence staining experiments.
results
1.Greater than 1.75μg/ml arsenic trioxide could significantly inhibit the growth of MDA-MB-435S cells,and arsenic trioxide have a dose effect in 1.75～28μg/ml concentration range(P<0.001).
2.Arsenic Trioxide can make the percentage of G0-G1 stage cells and G2/M stage cells increase in the MDA-MB-435S cell cycle,and make S stage cell decrease.To contrast with control group,all of the results have significant differences(p<0.05).
3.PI-flow single-dye experiments show that MDA-MB-435S cells do not have obvious apoptosis and MCF-7 cells have obvious apoptosis in 1、5、10、15、20μg/ml(p<0.05).
4.Streaming AnnexinⅤ/ PI double staining experiments show that the early apoptosis rate of MDA-MB-435S cells have no significant difference by As_2O_3 group(1、5、10、15、20μg/ml)compared with control group,and the early apoptosis rate of MDA-MB-435S cells have significant difference by As_2O_3 group(0.25、0.5、1、1.5、2μg/ml) compared with control group.With the action dose heightening,the rate of Apoptosis will be induced to increase obviously.MDA-MB-435S cells apoptosis probably induced by low concentrations of arsenic trioxide.
5.Immunohistochemical detection experiments show that the group of Arsenic Trioxide(0.25、0.5、1、5、10μg/ml) compared with control group can down-regulate the express of BCL-2 and BAX.
6.PI 33342 fluorescent staining experiments show that,under the same conditions,the group of Arsenic Trioxide(0.25、0.5、1、5、10μg/ml )compared with control group,apoptotic cells morphology can not be seen obviously in MDA-MB-435S cells and can be seen in MCF-7 cells.
conclusion
1.arsenic trioxide can inhibit MDA-MB-435S cell proliferation.
2.Arsenic trioxide can block MDA-MB-435S cell cycle at G0-G1 and G2-M phase,so that reduction into the S phase cells,probably induced by MDA-MB-435S cell apoptosis.
3.Arsenic Trioxide can down-regulate the express of BCL-2 and BAX. Arsenic trioxide are possible through reduced expression of BCL-2 to attain the inhibition MDA-MB-435S cells.Inhibition of the way should be studied further.
引文
[1]汤继英 三氧化二砷抗肿瘤机制及其与放化疗敏感性的关系[J]新乡医学院学报,2007,24(4):422-425
[2]蔡明,王国斌,陶凯雄,等 三氧化二砷治疗肿瘤作用机制的研究现状及进展[J]重庆医学,2007,36(15):1534
[3]孙洪德,马玲,胡晓晨等 癌灵1号结合中医辨证治疗急性早幼粒白血病[J]中国中西医结合杂志,1992,12(3):170-474
[4]曲志博等 三氧化二砷对乳腺癌作用的研究进展[J]中医实验外科杂志,2006,23(5):639-640
[5]马军 三氧化二砷在白血病治疗中的临床应用[J]中国医刊,2004,39(10):27-29
[6]胡博,陈正徐,夏俊等 As_2O_3对乳腺癌细胞的生长及端粒酶活性的影响[J]蚌埠医学院学报,2008,33(1):15-18
[7]徐波,王洁,卞度宏,等 三氧化二砷体外诱导宫颈癌细胞株凋亡及其机制的研究[J]实用医学杂志,2006,22(3):245-247
[8]刘连新,朱安龙,陈炜等 三氧化二砷对原发性肝癌的作用及其机理研究[J].中华外科杂志,2005,43(1):33-36
[9]王颖超,曹励之,张朝霞,等三氧化二砷诱导K562细胞线粒体跨膜电位的变化及其机制研究[J]实用儿科临床杂志,2005,20(1):18-19
[10]王南瑶,刘琳 三氧化二砷抗肿瘤机制及其临床应用新进展[J]临床肿瘤学杂志,2004,9(6):660
[11]邢茂,张思娟,叶鑫 三氧化二砷诱导肿瘤细胞凋亡途径的研究[J]中国药理学通报,2002,18(1):87
[12]Ling YH,jiang JD,Holland JF,etal.Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines[J].MolPharmacol,2002,62(3):529
[13]蒋明东 三氧化二砷与肝癌治疗的研究进展[J]重庆医学,2006,35(6):558
[14]李岚,张敬东,刘云鹏等 三氧化二砷对胃癌BGC-823细胞增殖及细胞周期的影响[J]肿瘤学杂志,2008,14(3):190-192
[15]王韫芳,孙红琰,李昕权,等 三氧化二砷对NB4及Ju-rkat细胞系端粒酶活性的抑制效应[J]中国实验血液学杂志,2003,11(4):359-362
[16]陈源汉,李明芬 三氧化二砷对恶性肿瘤的治疗作用[J]中华医学全科杂志,2003,2(3):108
[17]Adams JK,Cory s.The Bcl-2 protein family:arbiters of cell survival[J].Science,1998,281:1322-1326
[18]孙捷豪,张逸婧 三氧化二砷抗肿瘤机制的研究进展[J].辽宁医学杂志,2007,21(3):217-219
[19]Chen HY,Lin WH,Qin SK.Induction of arsenic trioxide on apoptosis hepatocarcinoma cell lines[J].ShijieHuaren Xiaohua Zazhi,2000,8(5):532-535.
[20]张鹏,王树叶,胡龙虎等 三氧化二砷治疗急性早幼粒细胞性白血病年总结-附242例分析[J]中华血液学杂志,2000,21(20):67-70
[21]Lew YS,Brown SL,Griffin RJ,etal.Arsenic trioxide causes selective necrosis in solid murine tunlors by vascular shutdown.Cancer Res,1999,59(24):6033-6037.
[22]马学斌,谷志远,宋海静等 三氧化二砷对Hela细胞hTERTmRNA表达的调节和对端粒酶活性的影响[J]军医进修学院学报,2004,25(1):26-28
[23]韩为东,赵亚力 乳腺癌与雌激素及有关内分泌治疗[J]现代肿瘤医学,2007,04:729-730
[24]杨红斌,付京,张盈华等 乳腺癌组织中孕激素受体与雌激素受体DNA结 合功能关系的研究[J]中国肿瘤临床,1999,26(10):743-746
[25]Russell KS,Haynes MP,etal.Estrogen stimulates heat shock Protein 90 binding to endothelial nitric oxides yentas in human vascular endothelial cells.Effects on calcium sensitivity and no release[J].Biol them,2000,275(7):5026-5030
[26]杨骅,郁琳琳 三氧化二砷诱导乳癌细胞的凋亡[J]中国肿瘤生物治疗杂志,1997,4(3):245
[27]Vahter M.Mechanisms of arsenic biotransformation[J].Toxicology.2002,181-182:211-217
[28]Gonzalez-FraileMI,Garcia-SanzR,MateosMV,etal.Methylenete-trahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis[J].Br J Haematol,2002,117(4):890-892
[29]MassMJ,WangL,Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells:a model for a mechanism of carcinogenesis[J]Mutat Res,1997,386(3):263-277
[30]Baj G,Arnulfo A,Deaglio S,et al.Arsenic Trioxide and breast cancer:analysis of the apoptotic,differentiation and immuno-dula-tory effects[J].Breast cancerResTreat,2002,73(1):61-73.
[31]Zhu Q,Zhang JW,ZhuHQ,etal.Synergic effects ofarsenic trioxide and cAMP during acute promyelocyticleukemia cellmaturation subtends a novelsignaling cross-talk[J].Blood,2002,99(3);1 014-1 022.
[32]曲志博,刘连新,陈炜等 三氧化二砷诱导乳线癌细胞系MCF-7凋亡的实验研究[J]中国普外基础与临床杂志,2007,14(2):159-162
[33]张丽娜,王留兴,樊青霞,等 三氧化二砷诱导雌激素受体阴性乳腺癌细胞株MDA-MB-435S凋亡和bcl-2、bax表达关系的研究[J]肿瘤基础与临床,2007,20(6):203-205
[34]姜影,佟丹丹,张颖 RUNX3、Bcl-2和Bax蛋白在乳腺癌中的表达及其意义[J]现代肿瘤医学,2007,15(7):943-945
[35]Lee KH,Im SA,Oh DY,et al.Prognostic significance of Bcl-2 expression in stage Ⅲ breast cancer patients who.had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy[J].BMC Cancer,2007,7(3):63.
[36]Yang WY,Liu CH,Chang CJ,et al.Proliferative activity,apoptsis and expression of oestrogen receptor and Bcl-2 oncoprotein in canine mammary gland tumours[J].J Comp Pathol,2006,134(1):70-79.
[37]Hyun Park W,Hee Cho Y,Won Jung C,etal.Arsenic trioxide inhibits the growth of the A498 renal cell carcinoma cells via cell cycle arrest or apoptosis[J].Biochem Biophys Commum,2003,300(1):230
[38]Murjo AJ.Clinical trials of arsenic trioxide in hematologic and solid tumors:overview of the National Cancer Institute Cooperative Research and Development StudiesLJ].Oncologist,2001,6(2):22
[39]王一帆,林丽珠 三氧化二砷诱导肿瘤细胞多药耐药细胞凋亡的研究进展[J]中药新药与临床药理,2004,15(2):139
[40]Woo SH,Park IC,Park MJ,etal Arsenic trioxide induces apoptosis through a reactive oxygen species dependent pathway and loss of mito-chondrialmembrane potential in HeL a cells[J].Int J On col 2002,21(1):57-63
[41]Carre M,Carles G,And erN,etal Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel induced,apoptosis[J].Biochem Pharmacy,2002,63(10):1831-1842
[42]Shen ZY,Shen WY,Chen MH,etal Mitochondria,calcium and nitric oxide in the apoptotic pathway of esophageal carcinoma cells induced by As_2O_3[J].Int JMolMed,2002,9(4):385-390
[43]Shen ZY,Shen J,Li QS,etal Morphological and functional changes of mitochondria in apoptotic esophageal carcinoma cells induced by arsenic trioxide [J].World J Gastroentero,2002,8(1):31-35
[44]Deng Y,Lin C,Zheng J,etal Over expression of Bcl-2 partly inhibits apoptosis of human cervical cancer Shi a cells induced by arsenic trioxide[J].Chin Med J,2000,113(1):84-88
[45]Mahieux R,Pise-Masison C,Gessain A,etal Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1-and type 2-infected cells by a caspase-3 dependent mechanism involving Bcl-2 cleavage[J].Blood,2001,98(13):3762-3769
[46]Park JW,Choi YJ,Jang MA,etal Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937cells[J].Biochem Biophys Res Commun,2001,286(4):726-734
[47]Jiang XH,Wong BS,Yuen ST,etal Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3[J].Int J Cancer,2001,91(2):173_179
[48]Chen GQ,Zhu JM,Shi XG,etal In vitro studies on cellular and molecular mechanisms of arsenic trioxide(As_2O_3) induces NB4 cell apoptosis with down regulation of bcl-2 expression and modulation of PMLRAR2/PML proteins[J].Blood,1996,88(3):1052-1061
[1]宋永熙,曲婷 亚砷酸注射剂的配制及临床应用[J]中国中医药科技,2008,15(5)
[2]金春海,金京春,马天泽等 单用三氧化二砷治疗急性早幼粒细胞白血病18例临床观察[J]延边大学医学学报,2007,30(2):130-131
[3]倪建华,陈国强,沈志祥等 静脉滴注三氧化二砷治疗急性早幼粒细胞白血病的药代动力学分析[J]中华血液学杂志,1997,18(5):250-253
[4]潘琳莉,郝强,张学勇 三氧化二砷治疗复发性急性早幼粒细胞白血病12例临床观察[J]中国中西医结合杂志,2006,26(8):731
[5]李敬东,贺立山,李志英等 三氧化二砷治疗慢粒加速期9例[J]新乡医学院学报,2003,20(5):347-348
[6]李敬东,韩效林,吴隼 三氧化二砷治疗难治性多发性骨髓瘤12例观察[J]医学创新研究,2007,4(29):136
[7]江伟,冯继锋,潘良熹等.三氧化二砷注射液治疗晚期原发性肝癌的临床观察[J]肿瘤基础与临床,2006,19(1):21-23
[8]秦叔逵,钱军,马军 三氧化二砷治疗原发性肝癌获缓解一例[J].临床肿瘤学杂志,1999,4(4):51-52
[9]秦叔逵,钱军,何泽明等 三氧化二砷治疗晚期胆囊癌[J].临床肿瘤学杂志.2000,54:286-287
[10]钱军,秦叔逵,何法明等.三氧化二砷治疗原发性肝胆癌的临床研究[J]中华肝脏病杂志,2001
[11]李凌浩,李惠民,李斌等 三氧化二砷为基础的联合方案治疗非霍奇金淋巴瘤5例[J]医学研究生学报,2008,21(3):333
[12]竺涵光,王跃平,张志愿 三氧化二砷经导管动脉介入治疗口腔鳞癌[J]口腔医学纵横杂志,2000,16(1):35-37
[13]蔡洪培,谢渭芬,张兴荣 三氧化二砷治疗恶性腹水1例[J]临床荟萃,2002,17(8):485
[1]HALSTED WS.The results of radical operations for thecure of carcinoma of thebreast[J].Ann Surg,1907,46:1-19.
[2]FISHER B.Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer[J].Cancer,1977,40:Suppl 1:574-87.
[3]陈莲芳 乳腺癌药物治疗进展[J]河北医学,2008,14(8):1000-1002
[4]雷大钊,雷建,黄炯强 乳腺癌外科治疗进展[J]岭南现代临床外科2008,8(2):150-152
[5]张建国,沈滨,李传乐 乳房保留术治疗乳腺癌22例体会[J]临床外科杂志,2008,16(1):66-67
[6]盛波 乳腺癌改良根治术56例临床分析[J]实用临床医学,2008,9(2):60-61
[7]朱丽萍,韩宝三,倪多等 不同手术方式对乳腺癌患者术后生存质量及婚姻质量的影响[J]新疆医科大学学报,2008,31(2):187-189
[8]江泽飞 乳腺癌药物治疗三大领域跨越发展[J]中国处方药,2008,70:69-72
[9]刘天亮,吴云 多西紫杉醇联合顺铂治疗晚期乳腺癌21例分析[J]中国误诊学杂志,2008,8(3):707
[10]张延新,刘恩娜 多西紫杉醇联合希罗达治疗晚期乳腺癌36例临床观察[J]山东医药,2007,47(34):15
[11]谢丹,杨海燕,黄梅等长春瑞滨联合吉西他滨治疗蒽环类化疗失败的复发转移乳腺癌[J]广西医学,2007,29(12):1871-1872
[12]贺新爱,陈海平,霍小珍NP和TP方案治疗乳腺癌复发转移的效果和安全性观察[J]医学理论与实践,2008,21(3):261-263
[13]宋士军,贾良 恩度(重组人血管内皮抑制素注射)联合卡培他滨治疗晚期乳腺癌的临床观察[J]中国实用医药,2008,3(12):22-23
[14]Fisher B,Broun A,Mamounas E,et al.Effect of preopexative chemotherapy on local- regional disease in women with operable breast cancer:findings frome National Surgical Adjuuvant Breat and Bowel Project B- 18.J Clin Oncol,1997,15,2483-2493.
[15]张斌,蔡正娥,张齐等,新辅助化疗用于手术乳腺癌的10年疗效[J]中国肿瘤临床,2002,29(3):157-160
[16]任秋英 76例进展期乳腺癌术前新辅助化疗疗效观察[J]中国医疗前沿,2008,3(4):75-76
[17]Doisneau Sixou S F,Serqio CM,Carroll J S,et al.Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells.Endocr Relat Cancer,2003,10:179-186.
[18]许骏,王本忠 乳腺癌内分泌治疗[J]中华乳腺病杂志,2008,2(3):324-330
[19]黄信孚 现代肿瘤学诊疗手册[M]北京:北京医科大学、中国协和医科大学联合出版社,1995:111
[20]Waeber M,Castiqlione Gertsch M,Dietrich D,et al.Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence:definitive results of a phase Ⅲ randomized trial(SAKK23/82 )comparing tamoxifen with observation.Ann Oncol,2003,14:1215 - 1221.
[21]Fisher B,Dignam J,Bryant J,et al.Five versusmore than five years of tamoxifen for lymph node2negative breast cancer:updated findings from the National SurgicalAdjuvantBreast and Bowel ProjectB214 Randomized Trial.J Natl Cancer Inst,2001,93:684 - 90.
[22]Ficker J.Letrozole better than tamoxifen in postmenopausalwomen.Lancetoncol,2005,6:137 - 138
[23]Pennery E.The role of endocrine therapies in reducing risk of recurrence in postmenopausalwomen with hormone receptor positive breast cancer.Eur JoncolNurs,2008,[Epub ahead ofp tint].
[24]CrivellariD,Sun Z,Coates A S,et al.Letrozole compared with tamoxifen for elderly patients with endocrine2responsive early breast cancer:the B IG 1298 trial.Clin Oncol,2008,26:1972 - 1979.
[25]Paridaens R,Dirix L,Beex L,et al.Promising results with exemestane in the first2line.treatment of metastatic breast cancer:a randomized phase Ⅱ EORTC trialwith a tamoxifen control.Clin Breast Cancer,2000,1:S19 - S21.
[26]沈坤炜,陈烂铭 乳腺癌辅助内分泌治疗的现状和展望[J]中华肿瘤杂志,2003,25(6):612.
[27]安永恒,丁爱萍 肿瘤合理用药[M]北京:人民卫生出版社,2005:520.
[28]杨保庆,汤明,阮培刚 来曲唑治疗绝经后晚期转移性乳腺癌疗效观察[J]实用医学杂志,2008,24(7):1217-1218
[29]王永霞,张爱玲,张蓉 来曲唑与他莫西芬在绝经后乳腺癌新辅助内分泌治疗中的应用[J]南方医科大学学报,2008,28(4):667-668
[30]曲仁伟 来曲唑与吡柔比星联合化疗治疗晚期乳腺癌临床研究[J]中国社区医师医学专业半月刊,2008:10(9)
[31]戚晓军,赵卫红,王怀瑾 乳腺癌的分子靶向治疗研究进展[J]2008,73(4):82-87
[32]任军 乳腺癌的分子靶向治疗[J]中国实用内科杂志,2007,27(24):1907-1910
[33]徐兵河 乳腺癌分子靶向治疗的研究进展[J]中国处方药,2008,53(8):38-41
[34]Cobleigh MA,Vogel CL,Tripathy D,et al.Multinational study of the efficacy and safety of humanized anti-HER2 monoclonalantibody in women who haveHER2-overexpressioningmetastaticbreast cancer thathas progressesd after chemotherapy for metastatic disease.J Clin Oncol,1999,17(9):2639-2648.
[35]Vogel CL,Cobleigh MA,Tripathy D,et al.Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overecpressing metastatic breast cancer.J Clin Oncol,2002,20:719-726.
[36]Slamon DJ,Leyland-JonesB,Shak S,etal.Use ofchemotherapy plus amonoclonalantibody againstHER2 for metastatic breastcancer thatoverexpresses HER2.N Engl JMed,2001,344:783-792.
[37]Pegram m,Hsu S,Lewis G;et al.Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.Oncogene,1999,18:2241-2251.
[38]Slamon D,Leyland-Jones B,Shak S,et al.Addition of Herceptin(humanized anti-HER-2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer(HER2+/MBC) markedly increases anticancer activity:a randomized,multinational controlled phase Ⅲ trial.Proc AmSoc Clin Oncol,1998,17:98a.
[39]CobleighMA,Miller K,LangmuirVK,et al.Phase Ⅱ dose escalation trial ofAvastin(bevacizumab) in women with previously treatedmetastatic breast cancer.BreastCancer ResTreat,2001,69:301(abstr).
[40]陈凌翔,周青,陈颖波Avastin(贝伐单抗)联合化疗治疗晚期恶性肿瘤临床观察[J]肿瘤基础与临床,2007,20(6):495-496
[41]BAUER K R,BROWN M,PAR ISE C A,et al.Descrip tive analysis of estrogen receptor(ER) - negative,progesterone recep tor(PR) - negative,and HER2-negative invasive breast cancer,the so -called trip le - negative phenotype:a population - based study from the California cancer Registry[J].Cancer,2007,109(9):1 721 - 1 728.
[42]CLEATOR S,HELLERW,COOMBES R C,et al.Trip le - negative breast cancer:therapeutic op tions[J].Lancet Oncol,2007,8(3):235 - 244.
[43]RAKHA E A,EL SAYED M E,GREEN A R,et al.Prognostic markers in trip lenegative breast cancer[J].Cancer,2007,109(1):25 - 32.
[44]袁中玉,王树森,高岩等 305例三阴乳腺癌患者的临床特征及预后因素分析[J]癌症,2008,27(6):561-565
[45]何劲松,王先明,关弘等 区域靶向化疗治疗激素受体与HER22三阴性乳腺癌的临床疗效观察[J]中华肿瘤防治杂志,2008,15(6):456-459
[1]唐汉钧 乳腺癌的中医临床与实验研究[J]中医药学刊,2003,21(2):168-172
[2]张勇 张宗歧治疗乳腺癌经验初探[J]山西中医学院学报,2008,9(2):38-40
[3]王银山,蔡光先,陈立峰中医药治疗乳腺癌概况[J]湖南中医杂志,2002,18(5):58-59
[4]孙波 刘尚义教授辨治乳腺癌经验[J]河南中医,2007,27(7):13-14
[5]汤秀红 王锦鸿教授治疗乳腺癌的经验[J]吉林中医药,2000(4):11
[6]张洪亮,王宁.乳腺癌辨治篡要[J]新疆中医药,2001,19(3):3-4
[7]朱世杰 李佩文治疗乳腺癌经验撷英[J]北京中医药,2008,27(3):173-175
[8]黎壮伟,陈锐深 中医药治疗晚期乳腺癌临证体会[J]湖南中医杂志,2005, 21(5):47-48
[9]孙贻安,刘晓菲 中医对乳腺癌的认识及术后治疗原则[J]中医药学刊,2005,23(1):180-182
[10]王萍、蒋益兰.扶正消癌方干预治疗晚期乳腺癌36例进行临床观察[J]中医药导报,2008,14(5):23,39
[11]欧阳华强,黄雯霞,刘鲁明等 消瘕方治疗乳腺癌术后110例的临床观察[J]上海中医药杂志,2006,40(6):50-51
[12]胡仕祥 中西医结合治疗乳腺癌72例进行临床观察[J]辽宁中医杂志,2008,35(6):900-901
[13]徐力,龚蔚 疏肝化瘀解毒方联合TE方案治疗乳腺癌15例[J]南京中医药大学学报,2008,24(1):66-67
[14]李晓璐 胡志敏教授治疗晚期乳腺癌46例经验总结[J]黑龙江中医药,2008(2).32-33
[1]姜泊,张亚历,周殿元(主编)分子生物学常用实验方法[M]北京:人民军医出版社,1996:170
[2]于静 三氧化二砷抗肿瘤研究[J]国际肿瘤学杂志,2007,34(2):104-106
[3]翟中和,王喜忠,丁明孝主编.细胞生物学[M]北京:高等教育出版社,2000:358-362
[4]郭晓红,刘立新Annexin V/PI流式细胞分析法和TUNEL法检测肝细胞凋亡的对比研究[J]山西医科大学学报,2008,39(5):476-479
[5]明玉华BCL-2、BAX、CD44V6在乳腺癌表达及预后的研究[J]现代中西医结合杂志,2007,16(27),3940-3942
[6]王淑婷、李清、刘超等 荧光排斥分析法在凋亡细胞形态学研究中的价值剖析[J]大连大学学报,2001,22(6):96-97
[2]蔡明,王国斌,陶凯雄,等 三氧化二砷治疗肿瘤作用机制的研究现状及进展[J]重庆医学,2007,36(15):1534
[3]孙洪德,马玲,胡晓晨等 癌灵1号结合中医辨证治疗急性早幼粒白血病[J]中国中西医结合杂志,1992,12(3):170-474
[4]曲志博等 三氧化二砷对乳腺癌作用的研究进展[J]中医实验外科杂志,2006,23(5):639-640
[5]马军 三氧化二砷在白血病治疗中的临床应用[J]中国医刊,2004,39(10):27-29
[6]胡博,陈正徐,夏俊等 As_2O_3对乳腺癌细胞的生长及端粒酶活性的影响[J]蚌埠医学院学报,2008,33(1):15-18
[7]徐波,王洁,卞度宏,等 三氧化二砷体外诱导宫颈癌细胞株凋亡及其机制的研究[J]实用医学杂志,2006,22(3):245-247
[8]刘连新,朱安龙,陈炜等 三氧化二砷对原发性肝癌的作用及其机理研究[J].中华外科杂志,2005,43(1):33-36
[9]王颖超,曹励之,张朝霞,等三氧化二砷诱导K562细胞线粒体跨膜电位的变化及其机制研究[J]实用儿科临床杂志,2005,20(1):18-19
[10]王南瑶,刘琳 三氧化二砷抗肿瘤机制及其临床应用新进展[J]临床肿瘤学杂志,2004,9(6):660
[11]邢茂,张思娟,叶鑫 三氧化二砷诱导肿瘤细胞凋亡途径的研究[J]中国药理学通报,2002,18(1):87
[12]Ling YH,jiang JD,Holland JF,etal.Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines[J].MolPharmacol,2002,62(3):529
[13]蒋明东 三氧化二砷与肝癌治疗的研究进展[J]重庆医学,2006,35(6):558
[14]李岚,张敬东,刘云鹏等 三氧化二砷对胃癌BGC-823细胞增殖及细胞周期的影响[J]肿瘤学杂志,2008,14(3):190-192
[15]王韫芳,孙红琰,李昕权,等 三氧化二砷对NB4及Ju-rkat细胞系端粒酶活性的抑制效应[J]中国实验血液学杂志,2003,11(4):359-362
[16]陈源汉,李明芬 三氧化二砷对恶性肿瘤的治疗作用[J]中华医学全科杂志,2003,2(3):108
[17]Adams JK,Cory s.The Bcl-2 protein family:arbiters of cell survival[J].Science,1998,281:1322-1326
[18]孙捷豪,张逸婧 三氧化二砷抗肿瘤机制的研究进展[J].辽宁医学杂志,2007,21(3):217-219
[19]Chen HY,Lin WH,Qin SK.Induction of arsenic trioxide on apoptosis hepatocarcinoma cell lines[J].ShijieHuaren Xiaohua Zazhi,2000,8(5):532-535.
[20]张鹏,王树叶,胡龙虎等 三氧化二砷治疗急性早幼粒细胞性白血病年总结-附242例分析[J]中华血液学杂志,2000,21(20):67-70
[21]Lew YS,Brown SL,Griffin RJ,etal.Arsenic trioxide causes selective necrosis in solid murine tunlors by vascular shutdown.Cancer Res,1999,59(24):6033-6037.
[22]马学斌,谷志远,宋海静等 三氧化二砷对Hela细胞hTERTmRNA表达的调节和对端粒酶活性的影响[J]军医进修学院学报,2004,25(1):26-28
[23]韩为东,赵亚力 乳腺癌与雌激素及有关内分泌治疗[J]现代肿瘤医学,2007,04:729-730
[24]杨红斌,付京,张盈华等 乳腺癌组织中孕激素受体与雌激素受体DNA结 合功能关系的研究[J]中国肿瘤临床,1999,26(10):743-746
[25]Russell KS,Haynes MP,etal.Estrogen stimulates heat shock Protein 90 binding to endothelial nitric oxides yentas in human vascular endothelial cells.Effects on calcium sensitivity and no release[J].Biol them,2000,275(7):5026-5030
[26]杨骅,郁琳琳 三氧化二砷诱导乳癌细胞的凋亡[J]中国肿瘤生物治疗杂志,1997,4(3):245
[27]Vahter M.Mechanisms of arsenic biotransformation[J].Toxicology.2002,181-182:211-217
[28]Gonzalez-FraileMI,Garcia-SanzR,MateosMV,etal.Methylenete-trahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis[J].Br J Haematol,2002,117(4):890-892
[29]MassMJ,WangL,Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells:a model for a mechanism of carcinogenesis[J]Mutat Res,1997,386(3):263-277
[30]Baj G,Arnulfo A,Deaglio S,et al.Arsenic Trioxide and breast cancer:analysis of the apoptotic,differentiation and immuno-dula-tory effects[J].Breast cancerResTreat,2002,73(1):61-73.
[31]Zhu Q,Zhang JW,ZhuHQ,etal.Synergic effects ofarsenic trioxide and cAMP during acute promyelocyticleukemia cellmaturation subtends a novelsignaling cross-talk[J].Blood,2002,99(3);1 014-1 022.
[32]曲志博,刘连新,陈炜等 三氧化二砷诱导乳线癌细胞系MCF-7凋亡的实验研究[J]中国普外基础与临床杂志,2007,14(2):159-162
[33]张丽娜,王留兴,樊青霞,等 三氧化二砷诱导雌激素受体阴性乳腺癌细胞株MDA-MB-435S凋亡和bcl-2、bax表达关系的研究[J]肿瘤基础与临床,2007,20(6):203-205
[34]姜影,佟丹丹,张颖 RUNX3、Bcl-2和Bax蛋白在乳腺癌中的表达及其意义[J]现代肿瘤医学,2007,15(7):943-945
[35]Lee KH,Im SA,Oh DY,et al.Prognostic significance of Bcl-2 expression in stage Ⅲ breast cancer patients who.had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy[J].BMC Cancer,2007,7(3):63.
[36]Yang WY,Liu CH,Chang CJ,et al.Proliferative activity,apoptsis and expression of oestrogen receptor and Bcl-2 oncoprotein in canine mammary gland tumours[J].J Comp Pathol,2006,134(1):70-79.
[37]Hyun Park W,Hee Cho Y,Won Jung C,etal.Arsenic trioxide inhibits the growth of the A498 renal cell carcinoma cells via cell cycle arrest or apoptosis[J].Biochem Biophys Commum,2003,300(1):230
[38]Murjo AJ.Clinical trials of arsenic trioxide in hematologic and solid tumors:overview of the National Cancer Institute Cooperative Research and Development StudiesLJ].Oncologist,2001,6(2):22
[39]王一帆,林丽珠 三氧化二砷诱导肿瘤细胞多药耐药细胞凋亡的研究进展[J]中药新药与临床药理,2004,15(2):139
[40]Woo SH,Park IC,Park MJ,etal Arsenic trioxide induces apoptosis through a reactive oxygen species dependent pathway and loss of mito-chondrialmembrane potential in HeL a cells[J].Int J On col 2002,21(1):57-63
[41]Carre M,Carles G,And erN,etal Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel induced,apoptosis[J].Biochem Pharmacy,2002,63(10):1831-1842
[42]Shen ZY,Shen WY,Chen MH,etal Mitochondria,calcium and nitric oxide in the apoptotic pathway of esophageal carcinoma cells induced by As_2O_3[J].Int JMolMed,2002,9(4):385-390
[43]Shen ZY,Shen J,Li QS,etal Morphological and functional changes of mitochondria in apoptotic esophageal carcinoma cells induced by arsenic trioxide [J].World J Gastroentero,2002,8(1):31-35
[44]Deng Y,Lin C,Zheng J,etal Over expression of Bcl-2 partly inhibits apoptosis of human cervical cancer Shi a cells induced by arsenic trioxide[J].Chin Med J,2000,113(1):84-88
[45]Mahieux R,Pise-Masison C,Gessain A,etal Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1-and type 2-infected cells by a caspase-3 dependent mechanism involving Bcl-2 cleavage[J].Blood,2001,98(13):3762-3769
[46]Park JW,Choi YJ,Jang MA,etal Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937cells[J].Biochem Biophys Res Commun,2001,286(4):726-734
[47]Jiang XH,Wong BS,Yuen ST,etal Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3[J].Int J Cancer,2001,91(2):173_179
[48]Chen GQ,Zhu JM,Shi XG,etal In vitro studies on cellular and molecular mechanisms of arsenic trioxide(As_2O_3) induces NB4 cell apoptosis with down regulation of bcl-2 expression and modulation of PMLRAR2/PML proteins[J].Blood,1996,88(3):1052-1061
[1]宋永熙,曲婷 亚砷酸注射剂的配制及临床应用[J]中国中医药科技,2008,15(5)
[2]金春海,金京春,马天泽等 单用三氧化二砷治疗急性早幼粒细胞白血病18例临床观察[J]延边大学医学学报,2007,30(2):130-131
[3]倪建华,陈国强,沈志祥等 静脉滴注三氧化二砷治疗急性早幼粒细胞白血病的药代动力学分析[J]中华血液学杂志,1997,18(5):250-253
[4]潘琳莉,郝强,张学勇 三氧化二砷治疗复发性急性早幼粒细胞白血病12例临床观察[J]中国中西医结合杂志,2006,26(8):731
[5]李敬东,贺立山,李志英等 三氧化二砷治疗慢粒加速期9例[J]新乡医学院学报,2003,20(5):347-348
[6]李敬东,韩效林,吴隼 三氧化二砷治疗难治性多发性骨髓瘤12例观察[J]医学创新研究,2007,4(29):136
[7]江伟,冯继锋,潘良熹等.三氧化二砷注射液治疗晚期原发性肝癌的临床观察[J]肿瘤基础与临床,2006,19(1):21-23
[8]秦叔逵,钱军,马军 三氧化二砷治疗原发性肝癌获缓解一例[J].临床肿瘤学杂志,1999,4(4):51-52
[9]秦叔逵,钱军,何泽明等 三氧化二砷治疗晚期胆囊癌[J].临床肿瘤学杂志.2000,54:286-287
[10]钱军,秦叔逵,何法明等.三氧化二砷治疗原发性肝胆癌的临床研究[J]中华肝脏病杂志,2001
[11]李凌浩,李惠民,李斌等 三氧化二砷为基础的联合方案治疗非霍奇金淋巴瘤5例[J]医学研究生学报,2008,21(3):333
[12]竺涵光,王跃平,张志愿 三氧化二砷经导管动脉介入治疗口腔鳞癌[J]口腔医学纵横杂志,2000,16(1):35-37
[13]蔡洪培,谢渭芬,张兴荣 三氧化二砷治疗恶性腹水1例[J]临床荟萃,2002,17(8):485
[1]HALSTED WS.The results of radical operations for thecure of carcinoma of thebreast[J].Ann Surg,1907,46:1-19.
[2]FISHER B.Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer[J].Cancer,1977,40:Suppl 1:574-87.
[3]陈莲芳 乳腺癌药物治疗进展[J]河北医学,2008,14(8):1000-1002
[4]雷大钊,雷建,黄炯强 乳腺癌外科治疗进展[J]岭南现代临床外科2008,8(2):150-152
[5]张建国,沈滨,李传乐 乳房保留术治疗乳腺癌22例体会[J]临床外科杂志,2008,16(1):66-67
[6]盛波 乳腺癌改良根治术56例临床分析[J]实用临床医学,2008,9(2):60-61
[7]朱丽萍,韩宝三,倪多等 不同手术方式对乳腺癌患者术后生存质量及婚姻质量的影响[J]新疆医科大学学报,2008,31(2):187-189
[8]江泽飞 乳腺癌药物治疗三大领域跨越发展[J]中国处方药,2008,70:69-72
[9]刘天亮,吴云 多西紫杉醇联合顺铂治疗晚期乳腺癌21例分析[J]中国误诊学杂志,2008,8(3):707
[10]张延新,刘恩娜 多西紫杉醇联合希罗达治疗晚期乳腺癌36例临床观察[J]山东医药,2007,47(34):15
[11]谢丹,杨海燕,黄梅等长春瑞滨联合吉西他滨治疗蒽环类化疗失败的复发转移乳腺癌[J]广西医学,2007,29(12):1871-1872
[12]贺新爱,陈海平,霍小珍NP和TP方案治疗乳腺癌复发转移的效果和安全性观察[J]医学理论与实践,2008,21(3):261-263
[13]宋士军,贾良 恩度(重组人血管内皮抑制素注射)联合卡培他滨治疗晚期乳腺癌的临床观察[J]中国实用医药,2008,3(12):22-23
[14]Fisher B,Broun A,Mamounas E,et al.Effect of preopexative chemotherapy on local- regional disease in women with operable breast cancer:findings frome National Surgical Adjuuvant Breat and Bowel Project B- 18.J Clin Oncol,1997,15,2483-2493.
[15]张斌,蔡正娥,张齐等,新辅助化疗用于手术乳腺癌的10年疗效[J]中国肿瘤临床,2002,29(3):157-160
[16]任秋英 76例进展期乳腺癌术前新辅助化疗疗效观察[J]中国医疗前沿,2008,3(4):75-76
[17]Doisneau Sixou S F,Serqio CM,Carroll J S,et al.Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells.Endocr Relat Cancer,2003,10:179-186.
[18]许骏,王本忠 乳腺癌内分泌治疗[J]中华乳腺病杂志,2008,2(3):324-330
[19]黄信孚 现代肿瘤学诊疗手册[M]北京:北京医科大学、中国协和医科大学联合出版社,1995:111
[20]Waeber M,Castiqlione Gertsch M,Dietrich D,et al.Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence:definitive results of a phase Ⅲ randomized trial(SAKK23/82 )comparing tamoxifen with observation.Ann Oncol,2003,14:1215 - 1221.
[21]Fisher B,Dignam J,Bryant J,et al.Five versusmore than five years of tamoxifen for lymph node2negative breast cancer:updated findings from the National SurgicalAdjuvantBreast and Bowel ProjectB214 Randomized Trial.J Natl Cancer Inst,2001,93:684 - 90.
[22]Ficker J.Letrozole better than tamoxifen in postmenopausalwomen.Lancetoncol,2005,6:137 - 138
[23]Pennery E.The role of endocrine therapies in reducing risk of recurrence in postmenopausalwomen with hormone receptor positive breast cancer.Eur JoncolNurs,2008,[Epub ahead ofp tint].
[24]CrivellariD,Sun Z,Coates A S,et al.Letrozole compared with tamoxifen for elderly patients with endocrine2responsive early breast cancer:the B IG 1298 trial.Clin Oncol,2008,26:1972 - 1979.
[25]Paridaens R,Dirix L,Beex L,et al.Promising results with exemestane in the first2line.treatment of metastatic breast cancer:a randomized phase Ⅱ EORTC trialwith a tamoxifen control.Clin Breast Cancer,2000,1:S19 - S21.
[26]沈坤炜,陈烂铭 乳腺癌辅助内分泌治疗的现状和展望[J]中华肿瘤杂志,2003,25(6):612.
[27]安永恒,丁爱萍 肿瘤合理用药[M]北京:人民卫生出版社,2005:520.
[28]杨保庆,汤明,阮培刚 来曲唑治疗绝经后晚期转移性乳腺癌疗效观察[J]实用医学杂志,2008,24(7):1217-1218
[29]王永霞,张爱玲,张蓉 来曲唑与他莫西芬在绝经后乳腺癌新辅助内分泌治疗中的应用[J]南方医科大学学报,2008,28(4):667-668
[30]曲仁伟 来曲唑与吡柔比星联合化疗治疗晚期乳腺癌临床研究[J]中国社区医师医学专业半月刊,2008:10(9)
[31]戚晓军,赵卫红,王怀瑾 乳腺癌的分子靶向治疗研究进展[J]2008,73(4):82-87
[32]任军 乳腺癌的分子靶向治疗[J]中国实用内科杂志,2007,27(24):1907-1910
[33]徐兵河 乳腺癌分子靶向治疗的研究进展[J]中国处方药,2008,53(8):38-41
[34]Cobleigh MA,Vogel CL,Tripathy D,et al.Multinational study of the efficacy and safety of humanized anti-HER2 monoclonalantibody in women who haveHER2-overexpressioningmetastaticbreast cancer thathas progressesd after chemotherapy for metastatic disease.J Clin Oncol,1999,17(9):2639-2648.
[35]Vogel CL,Cobleigh MA,Tripathy D,et al.Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overecpressing metastatic breast cancer.J Clin Oncol,2002,20:719-726.
[36]Slamon DJ,Leyland-JonesB,Shak S,etal.Use ofchemotherapy plus amonoclonalantibody againstHER2 for metastatic breastcancer thatoverexpresses HER2.N Engl JMed,2001,344:783-792.
[37]Pegram m,Hsu S,Lewis G;et al.Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.Oncogene,1999,18:2241-2251.
[38]Slamon D,Leyland-Jones B,Shak S,et al.Addition of Herceptin(humanized anti-HER-2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer(HER2+/MBC) markedly increases anticancer activity:a randomized,multinational controlled phase Ⅲ trial.Proc AmSoc Clin Oncol,1998,17:98a.
[39]CobleighMA,Miller K,LangmuirVK,et al.Phase Ⅱ dose escalation trial ofAvastin(bevacizumab) in women with previously treatedmetastatic breast cancer.BreastCancer ResTreat,2001,69:301(abstr).
[40]陈凌翔,周青,陈颖波Avastin(贝伐单抗)联合化疗治疗晚期恶性肿瘤临床观察[J]肿瘤基础与临床,2007,20(6):495-496
[41]BAUER K R,BROWN M,PAR ISE C A,et al.Descrip tive analysis of estrogen receptor(ER) - negative,progesterone recep tor(PR) - negative,and HER2-negative invasive breast cancer,the so -called trip le - negative phenotype:a population - based study from the California cancer Registry[J].Cancer,2007,109(9):1 721 - 1 728.
[42]CLEATOR S,HELLERW,COOMBES R C,et al.Trip le - negative breast cancer:therapeutic op tions[J].Lancet Oncol,2007,8(3):235 - 244.
[43]RAKHA E A,EL SAYED M E,GREEN A R,et al.Prognostic markers in trip lenegative breast cancer[J].Cancer,2007,109(1):25 - 32.
[44]袁中玉,王树森,高岩等 305例三阴乳腺癌患者的临床特征及预后因素分析[J]癌症,2008,27(6):561-565
[45]何劲松,王先明,关弘等 区域靶向化疗治疗激素受体与HER22三阴性乳腺癌的临床疗效观察[J]中华肿瘤防治杂志,2008,15(6):456-459
[1]唐汉钧 乳腺癌的中医临床与实验研究[J]中医药学刊,2003,21(2):168-172
[2]张勇 张宗歧治疗乳腺癌经验初探[J]山西中医学院学报,2008,9(2):38-40
[3]王银山,蔡光先,陈立峰中医药治疗乳腺癌概况[J]湖南中医杂志,2002,18(5):58-59
[4]孙波 刘尚义教授辨治乳腺癌经验[J]河南中医,2007,27(7):13-14
[5]汤秀红 王锦鸿教授治疗乳腺癌的经验[J]吉林中医药,2000(4):11
[6]张洪亮,王宁.乳腺癌辨治篡要[J]新疆中医药,2001,19(3):3-4
[7]朱世杰 李佩文治疗乳腺癌经验撷英[J]北京中医药,2008,27(3):173-175
[8]黎壮伟,陈锐深 中医药治疗晚期乳腺癌临证体会[J]湖南中医杂志,2005, 21(5):47-48
[9]孙贻安,刘晓菲 中医对乳腺癌的认识及术后治疗原则[J]中医药学刊,2005,23(1):180-182
[10]王萍、蒋益兰.扶正消癌方干预治疗晚期乳腺癌36例进行临床观察[J]中医药导报,2008,14(5):23,39
[11]欧阳华强,黄雯霞,刘鲁明等 消瘕方治疗乳腺癌术后110例的临床观察[J]上海中医药杂志,2006,40(6):50-51
[12]胡仕祥 中西医结合治疗乳腺癌72例进行临床观察[J]辽宁中医杂志,2008,35(6):900-901
[13]徐力,龚蔚 疏肝化瘀解毒方联合TE方案治疗乳腺癌15例[J]南京中医药大学学报,2008,24(1):66-67
[14]李晓璐 胡志敏教授治疗晚期乳腺癌46例经验总结[J]黑龙江中医药,2008(2).32-33
[1]姜泊,张亚历,周殿元(主编)分子生物学常用实验方法[M]北京:人民军医出版社,1996:170
[2]于静 三氧化二砷抗肿瘤研究[J]国际肿瘤学杂志,2007,34(2):104-106
[3]翟中和,王喜忠,丁明孝主编.细胞生物学[M]北京:高等教育出版社,2000:358-362
[4]郭晓红,刘立新Annexin V/PI流式细胞分析法和TUNEL法检测肝细胞凋亡的对比研究[J]山西医科大学学报,2008,39(5):476-479
[5]明玉华BCL-2、BAX、CD44V6在乳腺癌表达及预后的研究[J]现代中西医结合杂志,2007,16(27),3940-3942
[6]王淑婷、李清、刘超等 荧光排斥分析法在凋亡细胞形态学研究中的价值剖析[J]大连大学学报,2001,22(6):96-97